Inhibikase Therapeutics
IKT
11 hedge funds and large institutions have $1.12M invested in Inhibikase Therapeutics in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
10% more capital invested
Capital invested by funds: $1.02M → $1.12M (+$97.3K)
0.05% less ownership
Funds ownership: 11.59% → 11.53% (-0.05%)
8% less funds holding
Funds holding: 12 → 11 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$49.4K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$17K |
| 3 |
William Blair & Company
Chicago,
Illinois
|
+$13.4K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$6.52K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$15 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$49.6K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.25K |
| 3 |
Renaissance Technologies
New York
|
-$1.21K |
| 4 |
MG
Mather Group
Chicago,
Illinois
|
-$721 |
IKT Hedge Fund Activity: Q3 2024 in Review
11 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q3 2024, worth a combined $1.12M — up 9.5% from $1.02M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of IKT and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 4 added.
The largest buyer was Armistice Capital, adding an estimated $49.4K. The largest seller was Citadel Advisors, exiting entirely with an estimated $49.6K sold.
- 11 institutional investors held Inhibikase Therapeutics (IKT) as of Q3 2024, down from 12 in Q2 2024.
- Funds reported $1.12M of Inhibikase Therapeutics stock for Q3 2024, up 9.5% quarter-over-quarter.
- 1 fund opened new Inhibikase Therapeutics positions in Q3 2024 and 2 closed out, a net change of -1 holder.
- The largest Inhibikase Therapeutics buyer in Q3 2024 was Armistice Capital, an estimated $49.4K added.
- The largest Inhibikase Therapeutics seller in Q3 2024 was Citadel Advisors, an estimated $49.6K sold.
Based on aggregated 13F filings for Q3 2024.